🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Neoantigen specific TCR-T cell drug product

    Alaunos Therapeutics

    Gynecologic Cancer

    phase 2 mab terminated

    1 trial

  2. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    GastroEsophageal Cancer

    phase 2 small molecule active

    1 trial

  3. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Anatomic Stage I Breast Cancer

    phase 2 small molecule active

    1 trial

  4. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Early Stage HER2+ Breast Cancer

    phase 2 small molecule completed

    1 trial

  5. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Early-stage Breast Cancer

    phase 2 small molecule active

    1 trial

  6. Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive

    United Therapeutics Europe Ltd

    Contraception

    phase 2 small molecule completed

    1 trial

  7. Neulasta 6 mg solution for injection

    Istituto Gentili S.r.l.

    Severe chronic neutropenia (SCN)

    phase 2 small molecule active

    1 trial

  8. Nicotine gum and lozenge

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  9. Nilotinib followed by treatment-free

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia

    phase 2 small molecule completed

    1 trial

  10. Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Prevenar 13 suspension for injection pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Rotarix oral suspension in pre-filled oral applicator Rotavirus vaccine, live, Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IP

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 small molecule active

    1 trial

  11. Nimotuzumab

    Chinese University of Hong Kong

    Esophageal Cancer

    phase 2 small molecule completed

    1 trial

  12. Nimotuzumab

    The First People's Hospital of Lianyungang

    Esophageal Neoplasms

    phase 2 small molecule active

    1 trial

  13. Nimotuzumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  14. Nimotuzumab + SHR-1210

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  15. Novo Nordisk GlucaGen®

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  16. OBINUTUZUMAB, Zanubrutinib

    BeiGene

    Relapsed/Refractory Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  17. OLAPARIB, BEVACIZUMAB

    The George Institute

    Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer

    phase 2 small molecule active

    1 trial

  18. OMEPRAZOLE , ACETYLSALICYLIC ACID

    The George Institute

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  19. OMP-59R5

    Mereo BioPharma Group plc

    Stage IV Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  20. OMP-59R5

    Mereo BioPharma Group plc

    Stage IV Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  21. ONCOVIN 1 mg, solution injectable, CARBOPLATINE TEVA 10 mg/ml, solution pour perfusion, ENDOXAN 1000 mg, poudre pour solution injectable, ETOPOSIDE TEVA 20 mg/ml, solution à diluer pour perfusion, TEPADINA 15 mg powder for concentrate for solution for infusion, THIOTEPA GENOPHARM 15 mg, lyophilisat pour usage parentéral

    The George Institute

    Retinoblastoma

    phase 2 small molecule active

    1 trial

  22. OPDIVO 10 mg/mL concentrate for solution for infusion.

    The George Institute

    Relapsing/Refractory ALK+ Anaplastic Large cell Lymphoma

    phase 2 small molecule active

    1 trial

  23. OPDIVO 10 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Early stage triple negative breast cancer

    phase 2 small molecule active

    1 trial

  24. OPDIVO 10 mg/mL concentrate for solution for infusion., Anti-Fucosyl GM1 PET Tracer, ETOPOSIDE, CARBOPLATIN

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources